The Role of Neuromodulators in Refractory Functional Dyspepsia

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The study was designed to investigate the effect of central neuromodulators on refractory functional dyspepsia

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Treatments: Flupenthixol

Criteria

Inclusion Criteria:

• 18-70 years old;

• education level higher than middle school;

• met the Rome IV criteria for FD; absence of abnormalities on physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), and abdominal imaging and GI endoscopy within 6 months;

• absence of Helicobacter pylori infection;

• signed written informed consent for participation in the study.

Exclusion Criteria:

• evidence of organic digestive diseases;

• diabetes, cancer and other diseases might affect GI function;

• pregnancy, lactation or breastfeeding;

• a history of allergic reaction to any of the drugs used in the study;

• participation in other clinical trials in the previous 3 months.